Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 40202794.
- Also identified by DOI 10.1681/ASN.0000000680 and PMC identifier 12416945.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Non-<i>DNMT3A</i> clonal hematopoiesis of indeterminate potential was associated with CKD progression in a meta-analysis of 5654 individuals with CKD. In an adenine-induced CKD mouse model, <i>Tet2</i>-clonal hematopoiesis of indeterminate potential was linked to lower GFR, increased kidney inflammation, tubular injury, and fibrosis. Clonal hematopoiesis of indeterminate potential (CHIP) is a common inflammatory condition of aging that causes myriad end-organ damage. CHIP has been associated with incident AKI and kidney function decline in the general population, particularly mutations in CHIP genes other than <i>DNMT3A</i> (termed non-<i>DNMT3A</i> CHIP). Previous studies of CHIP in individuals with CKD had limited sample sizes and conflicting findings. We examined CHIP and CKD progression in four CKD cohorts (<i>N</i>=5654): the Chronic Renal Insufficiency Cohort, the African American Study of Kidney Disease, individuals with CKD from the BioVU biorepository, and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events. Primary outcomes were incident CKD progression (50% eGFR decline or kidney failure) and eGFR slope over time. In addition, kidney function and pathology were assessed in a <i>Tet2</i>-CHIP mouse model of CKD induced by dietary adenine. Across all cohorts, the average age was 66±11 years, with an average baseline eGFR of 43±15 ml/min per 1.73 m<sup>2</sup>, and 24% had CHIP. After meta-analysis, non-<i>DNMT3A</i> CHIP was associated with a 64% higher relative risk of incident CKD progression (hazard ratio, 1.64; 95% confidence interval, 1.00 to 2.68), with the strongest effect observed in individuals with baseline eGFR 30–60 ml/min per 1.73 m<sup>2</sup> (hazard ratio, 1.85; 95% confidence interval, 1.18 to 2.90). Non-<i>DNMT3A</i> CHIP carriers also exhibited a faster eGFR decline (<i>β</i>, −0.62±0.28 ml/min per 1.73 m<sup>2</sup> per year; <i>P</i> = 0.03). In a dietary adenine mouse model of CKD, <i>Tet2</i>-CHIP was associated with lower GFR as well as greater kidney inflammation, tubular injury, and tubulointerstitial fibrosis. Non-<i>DNMT3A</i> CHIP was associated with CKD progression among individuals with CKD. Furthermore, <i>Tet2</i>-CHIP mouse models support a causal role in kidney injury.